Pharmaceutical German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that a Phase III trial evaluating Nexavar (sorafenib) as an adjuvant treatment for patients with hepatocellular carcinoma (HCC, a form of liver cancer) who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. 11 March 2014